These results suggest that mGlu5 NAMs may be useful in the treatment of the motor and non-motor symptoms, as well as the dyskinesia resulting from the loss of dopaminergic neurons and long-term L-Dopa treatment. This evidence concerns the gene GRM5 and Dyskinesia.